Pfizer's FCPA settlement to top $60M; Valeant buys iNova for up to $698M;

 @FiercePharma: Regeneron prices wet AMD drug Eyela at $1850 per shot, $16K per yearr, compared with Roche's Lucentis at $24K annually. | Follow@FiercePharma

> Pfizer's settlement of U.S. foreign bribery probes will amount to more than $60 million, Wall Street Journal sources said, as a pharma-wide investigation of potential Foreign Corrupt Practices Act violations continues. Report

> Acquisition-hungry Valeant Pharmaceuticals has snapped up Australia's iNova Pharmaceuticals for up to $698 million, gaining a "beachhead" in Southeast Asia and South Africa. Report

> Members of the British parliament are investigating ongoing shortages of certain drugs, after allegations arose that the shortages have been caused by parallel trade. Report

> The European Patent Office granted a patent on the composition of GW Pharmaceuticals' recently approved drug Sativex. Report

> India's Dr Reddy's Laboratories said contract workers at its Andhra Pradesh manufacturing facility called off their strike and operations are back to normal. Report

> Foster children are being prescribed powerful antipsychotic drugs as frequently as some of the most mentally disabled kids, a new study finds. Report

> Omnicare said it has given the Federal Trade Commission information about its buyout offer for rival PharMerica. Report

Biotech News

 @FierceBiotech: With 20% of vote, Sanofi's Viehbacher is leading our poll on the most influential CEOs in pharma. Vote | Follow @FierceBiotech

 @JohnCFierce: If these Pharmasset drugs work as Gilead hopes, qualifies for '14 OK, then Gilead is a hero. If they don't, Gilead is a goat. Hero or goat. | Follow @JohnCFierce

 @RyanMFierce: Unfortunately for $REGN, it can undercut Lucentis price and still face uphill battle competing with off-label Avastin in wet AMD. | Follow @RyanMFierce

 @MaureenFierce: Celldex brain cancer vaccine increases survival in Phase II. Report | Follow @MaureenFierce

 @MarkHFierce: ImClone/Lilly's Erbitux and Roche's Tarceva as brain tumor treatment? Expanded indications would equal greater value. Story | Follow @MarkHFierce

Medical Device News

 

> Covidien to buy BARRX for $325M. News

> FDA to investigate stent shrinkage. Article

> BeneChill names former Boston Sci exec as new CEO. Item

> Survey: Irish medtech companies looking to hire next year. Piece

 

Biotech IT News

 

> Tufts to tackle tough issue of lengthy trial startups. Story

> Perceptive Informatics survey focuses on role of imaging in clinical trials. Report

> Biotech billionaire mounts digital attack on cancer. Report

> Scripps begins world's largest computer-based project against malaria. News

> Biotech heavyweight Art Levinson takes chairman job at Apple.  Article

And Finally... Debate over birth-control coverage rules has cropped up again, as President Obama weighs a broader exemption for institutions affiliated with religious groups. Report

Suggested Articles

Astellas and Seattle Genetics are out with Padcev-Keytruda combo data that may be good enough to snag an expedited regulatory review, analysts say.

Distributors had offered billions of dollars to wrap up opioid litigation, but that effort has suffered a major setback, WSJ reports.

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.